@kevjbyrne.bsky.socialThe mission of NEVER STOP NEVER QUIT is to raise funds, support treatment, and promote awareness in the fight against MS. 100% of the money we raise goes to our fight (I pay the cost to manage).
Please support our fight!
#NeverStopNeverQuitForThem #MultipleSclerosis
@jamaneurology.comAmong patients with relapsing #MultipleSclerosis, earlier and continuous ocrelizumab treatment was associated with better long-term relapse and disability control than delayed initiation after interferon beta-1a.
@morethanms.bsky.socialA little Saturday reading.
One MRI. Two essays. And a fear that didn’t end when the machine stopped.
A Sliver of Outside:
miguelallamani.com/notes/a-sliv...
Fear of the Final Fall:
miguelallamani.com/notes/fear-o...
@gregoryai.bsky.socialOligodendroglial damage and demyelination are common pathological features characterizing white matter and neurodegenerative disorders. Identifying the signaling pathways involved in myelin repair through oligodendroglial progenitor matu...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@gregoryai.bsky.socialTransferrin (Tf) has a major role in T cell activation and proliferation. Here, we investigated whether Tf exerts immunomodulatory effects on T cells and in development of T-cell driven experimental autoimmune encephalomyelitis (EAE). Wh...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@gregoryai.bsky.socialOligodendrocytes are the cells producing the myelin membrane around the axons in the central nervous system and, although apotransferrin (aTf) is required for oligodendrocyte differentiation, the underlying mechanisms are not fully under...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@kevjbyrne.bsky.socialA surprise after October Garage Dayz: no pain! My response is to push, push, push #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
@kevjbyrne.bsky.socialPlease donate to support our fight!
NeverStopNeverQuit.com/donate
#NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, a novel drug candidate targeting the enzyme behind myelin destruction in MS. With ~3 million people affected globally and no cure in sight, new approaches are urgently needed. #MultipleSclerosis #Biotech
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) has received FDA approval to advance Lucid-MS into phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in phase 1 and uses a distinct mechanism from existing MS therapies. #Biopharma #MultipleSclerosis
@gregoryai.bsky.socialNew clinical trial
Assessing the Validity and Reliability of the Language Memory Test for Use in a Belgian Population of People With Multiple Sclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA approval to advance Lucid-MS into Phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in Phase 1 and features a proprietary mechanism that sets it apart from existing therapies. #Biopharma #MultipleSclerosis
@neurologyadvisor.bsky.socialAlthough slowly expanding #lesions represent a small fraction of overall T2 lesions, they are highly prevalent across #MultipleSclerosis subtypes and partially overlap with paramagnetic rim lesions.
@newsramp.comQuantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, its first-in-class neuroprotective treatment for progressive multiple sclerosis, following FDA clearance. #MultipleSclerosis #ClinicalTrials
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) signs Study Start-Up Agreement with Thermo Fisher Scientific to advance its Phase 2 trial of Lucid-MS, a first-in-class neuroprotective treatment for progressive multiple sclerosis. #MultipleSclerosis #Biopharma
@modernbuddhism.bsky.social#meditation #modernbuddhismpodcast #peaceofmind #buddhism #meditate #ms #multiplesclerosis #multiplesclerosisawareness
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into Phase 2 trials for multiple sclerosis while its unbuzzd spinout delivers a 7% royalty stream up to $250M. A dual-track strategy targeting both pharma and wellness markets. #Biotech #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into a Phase 2 MS trial while holding a 20% stake and 7% royalty stream in alcohol-metabolism product unbuzzd. A dual pipeline worth watching. #Biotech #MultipleSclerosis